Cancer survivors are at high risk for human papillomavirus (HPV)-related morbidities; we estimated the prevalence of HPV vaccine initiation in cancer survivors versus the US population and examined predictors of noninitiation.
INTRODUCTION
Modern advances in treatment of pediatric cancer have resulted in a rapidly growing population of survivors. 1 A substantial number of these survivors are adolescents and young adults (AYAs)a group at highest risk for sexually transmitted infection (STI). 2, 3 Human papillomavirus (HPV) is the most common STI in the United States 3 ; HPV prevalence among sexually active AYAs ranges from 44.8% in females 4 to 51.2% in males, 5 with an estimated 6.9 million AYAs becoming newly infected annually. 3 and Prevention's Advisory Committee on Immunization Practices (ACIP) since 2006 for girls 25 and since 2011 for boys. 26 ACIP recommends HPV vaccine initiation as early as 9 years of age. 27 Recommendations extend to 26 years of age for females and 21 years of age for males (but to age 26 for male special populations, including individuals with cancer). 28 Since the initial ACIP recommendations, HPV vaccine uptake in the United States has remained low. 29, 30 Factors associated with low uptake in the general population include lack of HPV-specific knowledge, 31,32 health beliefs (ie, negative attitude toward vaccines, low perceived susceptibility to and severity of HPV-related disease, lack of perceived vaccine benefits, presence of perceived barriers to vaccination, low self-efficacy, and concern that vaccination encourages sexual activity), [33] [34] [35] communication difficulties regarding sexual health, 36 vaccine safety concerns, 37 social and environmental influences, 33 and lack of health care provider recommendation for the vaccine. 34 There is a paucity of data regarding HPV vaccine uptake among young cancer survivors, 38 particularly among males and those recently completing cancer therapy.
This study addressed these gaps by estimating the prevalence of HPV vaccine initiation among young cancer survivors 1 to 5 years after completion of therapy. The study compared vaccine uptake in survivors with the general US population and identified factors associated with HPV vaccine noninitiation.
METHODS

Study Design
We conducted a cross-sectional survey (NCT01492582) to determine the prevalence of HPV vaccine initiation and predictors of noninitiation in a cohort of young cancer survivors ages 9 to 26 years, identified from five National Cancer Institute-designated Comprehensive Cancer Centers. HPV vaccine initiation rates among survivors were compared with age-, sex-and year-matched US population peers using data from the National Immunization Survey-Teen (NIS-Teen; ages 13 to 17 years), [39] [40] [41] [42] and National Health Interview Survey (NHIS; ages 18 to 26 years). [43] [44] [45] [46] 
Participants
Eligible patients included cancer survivors who were in remission and had completed therapy 12 to 60 months before survey participation, ages 9 to 26 years, English-or Spanish-speaking, and scheduled for a clinic visit at a participating site (St. Jude Children's Research Hospital, City of Hope, University of Michigan, Emory University, or University of Alabama at Birmingham). To reduce participation bias, eligible patients were identified from clinic rosters and approached on arrival for routine appointments. Informed consent/assent was obtained in the patient or parent's preferred language according to site-specific institutional review board requirements.
Study Instruments
Survey. Eligible survivors ($ 18 years old) or parents (of survivors 9 to 17 years old) completed the HPV Vaccination Survey that elicited sociodemographic information, current HPV vaccination status (including age at initiation and number of doses received, if any). The survey also elicited information pertaining to receipt of provider recommendation regarding HPV vaccination, 47-49 knowledge regarding HPV infection and related health risks, 32 HPV-related health beliefs (including perceived susceptibility to and severity of HPV-related illness; general vaccine attitudes and beliefs 34 ; and perceived barriers [eg, concerns about cost, logistics, safety, or vaccines in general] and benefits [eg, STI and cancer prevention], cues to action, self-efficacy, and decision making related to HPV vaccination 33,35,50-54 ), health-related practices, 55 socio-environmental influences, 33,54,56 HPV-specific communication, 36 and parent-child sexual communication. 57 
Population Comparison Data
Data from the NIS-Teen (ages 13 to 17 years) 29,59-61 and NHIS (ages 18 to 26 years) 46,62-64 2012 to 2015 surveys were used to compare survivors' HPV vaccine initiation rates with those in the general population using age group (ages 13 to 17 years; ages 18 to 26 years), sex, and survey-year (2012, 2013, 2014, or 2015) matched comparisons. In these national surveys representative of the US population, receipt of HPV vaccine is self-or parent-reported via telephone interview, 59,62 providing a comparable comparison with the self-/parent-reported data collected in our survey. 65
Statistical Analysis
Population comparison. The primary end point was self-or parentreported HPV vaccine initiation (ie, receipt of one or more HPV vaccine doses). HPV vaccine initiation rates for the 13-to 26-year-old cancer survivor cohort and age-group-matched and sex-matched US population data (NIS-Teen [ages 13 to 17 years] and NHIS [ages 18 to 26 years]) were compared in unadjusted descriptive models using x 2 tests for the entire cohort (male/female ages 13 to 26 years) and stratified by age group (teens 13 to 17 years; young adults 18 to 26 years) and sex. Multivariable logistic regression was used to compare vaccine initiation in survivors versus population data, adjusting for age, sex, race/ethnicity, census region, education level, household income, and data collection year. Separate age-stratified (teens 13 to 17 years, young adults 18 to 26 years) and sexstratified (males 13 to 26 years, females 13 to 26 years) models were also developed, adjusting for race/ethnicity, census region, household income, education level, data collection year, and sex (for age-stratified models) or age (for sex-stratified models). The same techniques were used to compare HPV vaccine dose completion in 13-to 26-year-old survivors versus population.
Within cancer survivor analysis. Predictors of HPV vaccine noninitiation were determined using logistic regression. To account for multiple comparisons, two-sided tests with P , .01 were considered statistically significant. Associations of vaccine noninitiation with sociodemographic, clinical, and survey response data were first examined univariably using logistic regression. Variables with P , .1 were then included in a multivariable model, followed by stepwise backward variable elimination to obtain a final parsimonious model composed of explanatory variables with P , .01. Race, primary cancer diagnosis, treatment (chemotherapy [yes/no], radiation [yes/no], HCT [yes/no]), and time from therapy completion were included in the model regardless of P values. Additional models were developed for subgroups stratified by age/sex. PROC LOGISTIC of SAS (version 9.4; SAS Institute, Cary, NC) was used for analysis.
RESULTS
Of the 1,227 eligible patients (or parents) approached, 1,046 (85.2%) consented to participate and 982 (80.0%) returned evaluable surveys (Fig 1) . Participants were more likely to be older (mean age, 16.3 v 15.4 years; P = .005) and non-Hispanic white (65.5 v 58.8%; P = .006) compared with nonparticipants, respectively (Appendix Table A1 , online only). Clinical and sociodemographic jco.org characteristics are listed in Table 1 . Cancer survivors were a median of 16.3 (range, 9.0 to 26.9) years old and completed therapy a median of 2.7 (range, 1.0 to 5.0) years before study participation; 54.6% were male, 65.5% were non-Hispanic white, 36.2% had a diagnosis of acute leukemia, 93.0% received chemotherapy, and 19.3% had undergone HCT.
Prevalence of HPV Vaccine Initiation
Among 13-to 26-year-old cancer survivors, 23.8% (95% CI, 20.6% to 27.0%) initiated HPV vaccination, compared with 40.5% (95% CI, 40.2% to 40.7%) in the general population (P , .001). When stratified by age, HPV vaccine initiation rates were significantly lower among 13-to 17-year-old survivors than agematched population comparisons (22.0%; 95% CI, 17.3% to 26.7% v 42.5%; 95% CI, 42.2% to 42.8%; P , .001). In contrast, initiation rates among 18-to 26-year-old survivors were comparable to age-matched general population peers (25.3% v 24.2%; P = .6). Stratifying by sex within each age group revealed that HPV vaccine initiation rates in 13-to 17-year-old survivors were significantly lower than population comparisons (females, 32.6% v 51.9%; P , .001; males, 14.0% v 33.8%; P , .001). Within the 18to 26-year-old age group, initiation rates among female survivors were higher than in the general population (45.7% v 38.2%; P = .04), whereas rates in male survivors were similar to population comparisons (7.5% v 8.3%; P = .7; Fig 2A) . Prevalence of vaccine initiation among 9-to 12-year-old survivors was 5.9% (95% CI, 3.3% to 8.6%) overall; the prevalence was 8.0% among females and 4.2% among males. No population comparisons are available for this age group.
Using multivariable logistic regression and adjusting for age, sex, race/ethnicity, US census region, education level, household income, and year of data collection, cancer survivors were more likely to be vaccine-naïve compared with general population peers (odds ratio [OR], 1.7; 95% CI, 1.4 to 2.1; P , .001). In separate age-and sex-stratified models, the odds of HPV vaccine noninitiation among 18-to 26-year-old survivors were similar to the general population overall (OR, 1.2; 95% CI, 0.9 to 1.6; P = .3), and when stratified by sex (females: OR, 1.0; 95% CI, 0.7 to 1.5; P = .8; males: OR, 1.5; 95% CI, 0.8 to 2.8; P = .2). In contrast, the odds of being vaccine-naïve were significantly higher in 13-to 17-year-old survivors compared with the general population (OR, 2.5; 95% CI, 1.9 to 3.4; P , .001), as well as when stratified by sex (females: OR, 2.3; 95% CI, 1.6 to 3.4; P , .001; males: OR, 2.9; 95% CI, 1.9 to 4.6; P , .001; Table 2 ).
HPV Vaccine Doses Received and Series Completion Rates
The proportion (95% CI) of 13-to 26-year-olds receiving at least one, two, or three HPV vaccine doses in cancer survivors compared with the general population were as follows: one or more doses, 23.8% (20.6% to 27.0%) versus 40.5% (40.2% to 40.7%); two or more doses, 18.1% (15.1% to 21.0) versus 29.1% (28.8% to 29.3%); three or more doses, 13.5% (10.9% to 16.0%) versus 20.8% (20.6% to 21.0%), respectively (P , .001 for all comparisons; Fig 2B) . The odds of survivors not receiving two or more doses or three or more doses, regardless of receipt of the first dose, were higher than the general population, respectively (two or more doses: OR, 1.2; 95% CI, 1.0 to 1.5; P = .04; three or more doses: OR, 7.5; 95% CI, 6.1 to 9.4; P , .001). However, among those survivors who received at least one dose, completion rates (95% CI) for the three-dose series were similar for survivors and the general population: 56.5% (48.9% to 64.2%) versus 54.0% (53.6% to 54.4%), respectively (P = .5).
Risk Factors for HPV Vaccine Noninitiation Among Cancer Survivors
All age groups. In the multivariable logistic regression model restricted to cancer survivors and adjusted for cancer diagnosis, treatment type (chemotherapy, radiation, HCT), time from therapy completion, and race/ethnicity, significant predictors of HPV vaccine noninitiation among 9-to 26-year-olds included lack of provider recommendation (OR, 10.8; 95% CI, 6.5 to 18.0; P , .001), perceived lack of insurance coverage for the vaccine (OR, 6.6; 95% CI, 3.9 to 11.0; P , .001), male sex (OR, 2.9; 95% CI, 1.7 to 4.8; P , .001), endorsement of barriers to HPV vaccination (OR, 2.7; 95% CI, 1.6 to 4.6; P , .001), and age (9 to 12 years of age: OR, 3.7; 95% CI, 1.8 to 7.6; P , .001; 18 to 26 years of age: OR, 0.5,;95% CI, 0.3 to 0.9; P = .02; reference group: 13 to 17 years of age; Table 3 ).
Stratified by age group. Decreased risk of vaccine noninitiation was associated with increasing age in 9-to 12-year-old survivors (OR, 0.3 per year; 95% CI, 0.1 to 0.8; P = .009). An increased risk of noninitiation was associated with endorsement of barriers to HPV vaccination in 13-to 17-year-old survivors (OR, 3.7; 95% CI, 1.5 to 9.6; P = .006); and with male sex in 18-to 26-year-olds: OR, 5.8; 95% CI, 2.1 to 15.7]; P , .001). Perceived lack of insurance coverage for the HPV vaccine was associated with vaccine noninitiation among 13-to 17-year-olds: OR, 7.2; 95% CI, 3.2 to 16.5; P , .001; and 18-to 26-year-olds: OR, 10.3; 95% CI, 4.0 to 26.5; P , .001). Lack of provider recommendation was a significant predictor of HPV vaccine noninitiation across all age groups (9-12 years of age: OR, 13.0; 95% CI, 1.9 to 89.6; P = .009; 13 to 17 years of age: OR, 7.5; 95% CI, 3.1 to 18.1; P , .001; 18 to 26 years: OR, 23.3; 95% CI, 9.9 to 55.1; P , .001; Appendix Tables A2, A3, and A4). jco.org
Predictors of Vaccine Noninitiation Among Survivors Receiving a Provider Recommendation
Seventy-two percent of study participants reported a lack of provider recommendation regarding HPV vaccine; only 5% of these survivors reported initiating the vaccine (Fig 3) . Among the 28% of survivors who received a provider recommendation, 51% reported vaccine initiation. Predictors of vaccine noninitiation among those who had received a provider recommendation included perceived lack of insurance coverage for HPV vaccine (OR, 7.5; 95% CI, 3.7 to 15.3; P , .001); endorsement of barriers to HPV vaccination (OR, 3.4; 95% CI, 1.6 to 6.9; P = .001); and age 9 to 12 years (OR, 5.0; 95% CI, 1.9 to 13.1; P , .001; reference group: 13 to 17 years). Older survivors (18 to 26 years) with provider recommendations were more likely to initiate compared with 13-to 17-year-olds (OR [vaccine noninitiation] 0.24; 95% CI, 0.1 to 0.5; P , .001; Appendix Table A5 ).
DISCUSSION
To our knowledge, this is the first study to compare HPV vaccine initiation rates in young cancer survivors with those in the general population and to identify predictors of vaccine noninitiation in this vulnerable population. In this large study from five comprehensive cancer centers across the United States, we found that among survivors age 13 to 26, only 24% of the survivors initiated HPV vaccination, with just 13.5% completing the three-dose series. Survivors were significantly more likely to be vaccine-naïve compared with their general population peers. These findings raise significant concerns, because they suggest that over 85% of young cancer survivors may lack protection against vaccinepreventable HPV, placing them at risk for infection and subsequent HPV-related morbidity, including malignancies. Cancer survivors are at increased risk for subsequent HPV-associated malignancies compared with the general population 24,38 and thus would benefit from HPV vaccination.
The strongest predictor of HPV vaccine noninitiation for both male and female survivors across all age groups was lack of provider recommendation. Only 28% of survivors reported receiving such a recommendation, and those who lacked provider recommendation were at 10-fold increased risk for vaccine noninitiation compared with those receiving a recommendation. These findings align with previous research in the general population, demonstrating that lack of provider recommendation for HPV vaccination is a robust predictor for vaccine noninitiation. [66] [67] [68] [69] Of additional concern is that cancer survivors often receive medical care from both primary and subspecialty providers, and clear delineation among these providers regarding responsibility for vaccines may be lacking. In a recent study of subspecialists caring for adolescents with chronic medical conditions (including cancer), lack of communication between subspecialists and primary medical providers was identified as a significant barrier to HPV vaccine initiation. 70 Perceived lack of insurance coverage for HPV vaccine was a significant predictor of vaccine noninitiation among survivors, particularly among those who received a provider recommendation (7.5-fold increased risk of noninitiation). Although the Affordable Care Act mandates that most insurance plans cover preventive services, including vaccines, without a copayment or deductible, 71 employer-sponsored plans in place before the Affordable Care Act implementation are exempt from this provision. During the first (2012) and last (2015) years of our survey, 48% and 25% of workers, respectively, were covered by such exempt employer-sponsored plans. 72, 73 In addition, the federally funded Vaccines for Children Program provides free vaccine coverage to medically uninsured and Medicaid-eligible children in the United States, but does not provide coverage to some underinsured youth or to those over 18 years of age. 74 Lack of insurance coverage is a risk factor for vaccine noninitiation in the general population. [75] [76] [77] Given the multiple regulations and exemptions affecting insurance coverage for vaccines in the United States, it is possible that survivors perceive lack of insurance coverage for HPV vaccine as a significant barrier, whether or not this is actually the case. With recent changes in HPV vaccine formulation (ie, sole availability of nonvalent vaccine) 78 and administration schedules (from three-dose to two-dose series for healthy 9-to 14-year-olds, although not applicable to patients with cancer), 79 and with current uncertainties regarding national health care policies, 80 continued monitoring of the effect of insurance coverage on HPV vaccination is important.
Additional predictors of vaccine noninitiation included male sex, endorsement of barriers to vaccine receipt, and younger age. Despite low rates of vaccine uptake for males in the general population, 35,61,81 vaccinating males is critical in preventing anogenital cancers. 82-84 Nevertheless, our findings suggest that rates of vaccine uptake in male cancer survivors are suboptimal. Endorsement of barriers to vaccine receipt has also been associated with low vaccine uptake in the general population, but seems to be mitigated by vaccine endorsement and recommendation by medical providers. 35, 85 Maximum HPV vaccine benefit occurs when administration precedes sexual debut, so it is concerning that younger age was associated with vaccine noninitiation. In the general population, factors shown to influence age at vaccine initiation include provider preferences for vaccinating older adolescents and parental beliefs that their child is too young for vaccination. 77, [86] [87] [88] Although, to our knowledge, this is the first large study to report the prevalence and correlates of HPV vaccine noninitiation in young male and female cancer survivors, this work needs to be considered in the context of its limitations. This cohort was limited to survivors who were 1 to 5 years after treatment completion, and we used self-or parent-report of vaccine history. Although determining HPV vaccination history via medical record review may be more accurate in certain cases, overall, the validity of self-reported HPV vaccination has been demonstrated among both healthy young adults and those surviving childhood cancer. 65, 89 We excluded survivors who did not return for a clinic visit, which could have resulted in selection bias; however, survivors with less contact with the health care system may have been even less likely to receive the vaccine. Multiple testing and type I error are always challenges in observational studies; we used P , .01 as a conservative cut point, but results with P values near this cut point should be viewed with caution.
Because our study focused on survivors followed in the United States, when taken in the larger global context, our findings are even more concerning. Other developed countries, including the United Kingdom, Australia, Norway, Sweden, and Denmark, have achieved . 80% vaccine initiation rates and 70% completion rates in targeted general population birth cohorts. 90,91 Most of these countries have universal health care coverage and school-based HPV immunization programs. Lack of universal health care coverage in the United States and local/state control of school immunization requirements and programs 92 may contribute to low (ie, approximately 40% initiation rate for 13-to 26-yearolds) HPV vaccine uptake in the United States. Nevertheless, to our knowledge, there are no reports of HPV vaccine uptake among cancer survivors in any country outside of the United States; therefore, vaccine uptake among the vulnerable cancer survivor population in countries with high rates of HPV vaccination in the general population remains unknown and offers an opportunity for future research.
In conclusion, we found that only a small proportion of young cancer survivors initiated HPV vaccination despite increased vulnerability to HPV-related morbidity in this population. We also found that predictors of vaccine noninitiation in survivors were largely the same as those reported in the general population. In addition, despite the clear association between provider recommendation and vaccine initiation, we found that most survivors had not received a recommendation from their provider prompting vaccine initiation. Additional research is needed to delineate specific barriers that may be unique to the survivor population and that may inform future interventions to promote HPV vaccine uptake among young cancer survivors. Abbreviation: SD, standard deviation. *Nonparticipants comprised those eligible patients/parents who were approached regarding study participation but either refused participation (n = 181) or consented but did not return a survey (n = 46) or returned an inevaluable survey (n = 18). Inevaluable surveys were defined as those surveys that did not contain a response to the item that queried the survivor's human papillomavirus vaccine initiation status (ie, human papillomavirus vaccine initiation v noninitiation, the primary study outcome). 
